Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Tag
  • C-Myc
    (3)
  • C-6xHis
    (1)
  • C-His
    (1)
  • C-hFc
    (1)
  • N-10xHis
    (3)
  • N-6xHis
    (1)
  • N-GST
    (2)
  • Tag Free
    (2)
TargetMol | Tags By Expression System
  • Baculovirus Insect Cells
    (1)
  • E. coli
    (7)
  • HEK293 Cells
    (3)
TargetMol | Tags By Species
  • Human
    (7)
  • Mouse
    (3)
  • Rat
    (1)
Filter
Search Result
Results for "

hypertrophic

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    11
    TargetMol | Activity
  • Peptide Products
    1
    TargetMol | inventory
  • Recombinant Protein
    11
    TargetMol | natural
TargetMolTargetMolCompare
CTGF/CCN2 Protein, Human, Recombinant
TMPJ-01161
CTGF CCN2 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 16-25 KDa and the accession number is Q5M8T4.
  • $129
7-10 days
Size
QTY
TargetMolTargetMolCompare
CTGF/CCN2 Protein, Human, Recombinant (His)
TMPH-01069
Major connective tissue mitoattractant secreted by vascular endothelial cells. Promotes proliferation and differentiation of chondrocytes. Mediates heparin- and divalent cation-dependent cell adhesion in many cell types including fibroblasts, myofibroblasts, endothelial and epithelial cells. Enhances fibroblast growth factor-induced DNA synthesis. CTGF CCN2 Protein, Human, Recombinant (His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 15.1 kDa and the accession number is P29279.
  • $198
20 days
Size
QTY
TargetMolTargetMolCompare
CTGF/CCN2 Protein, Human, Recombinant (hFc)
TMPJ-01162
CTGF CCN2 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with C-Fc tag. The predicted molecular weight is 67-81 KDa and the accession number is Q5M8T4.
  • $184
7-10 days
Size
QTY
TargetMolTargetMolCompare
CTGF/CCN2 Protein, Mouse, Recombinant (GST)
TMPH-02568
Major connective tissue mitoattractant secreted by vascular endothelial cells. Promotes proliferation and differentiation of chondrocytes. Mediates heparin- and divalent cation-dependent cell adhesion in many cell types including fibroblasts, myofibroblasts, endothelial and epithelial cells. Enhances fibroblast growth factor-induced DNA synthesis.
  • $284
20 days
Size
QTY
TargetMolTargetMolCompare
TRIM63 Protein, Human, Recombinant (His & Myc)
TMPH-01271
E3 ubiquitin ligase. Mediates the ubiquitination and subsequent proteasomal degradation of CKM, GMEB1 and HIBADH. Regulates the proteasomal degradation of muscle proteins under amino acid starvation, where muscle protein is catabolized to provide other organs with amino acids. Inhibits de novo skeletal muscle protein synthesis under amino acid starvation. Regulates proteasomal degradation of cardiac troponin I TNNI3 and probably of other sarcomeric-associated proteins. May play a role in striated muscle atrophy and hypertrophy by regulating an anti-hypertrophic PKC-mediated signaling pathway. May regulate the organization of myofibrils through TTN in muscle cells.
  • $284
20 days
Size
QTY
TargetMolTargetMolCompare
LOXL2 Protein, Mouse, Recombinant (His)
TMPY-00203
Lysyl oxidase homolog 2, also known as Lysyl oxidase-like protein 2, Lysyl oxidase-related protein 2, Lysyl oxidase-related protein WS9-14 and LOXL2, is a secreted protein that belongs to the lysyl oxidase family. LOXL2 contains four SRCR domains. The lysyl oxidase family is made up of five members: lysyl oxidase (LOX) and lysyl oxidase-like 1-4 ( LOXL1, LOXL2, LOXL3, LOXL4 ). All members share conserved C-terminal catalytic domains that provide for lysyl oxidase or lysyl oxidase-like enzyme activity; and more divergent propeptide regions. LOX family enzyme activities catalyze the final enzymatic conversion required for the formation of normal biosynthetic collagen and elastin cross-links. LOXL2 is expressed by pre-hypertrophic and hypertrophic chondrocytes in vivo, and that LOXL2 expression is regulated in vitro as a function of chondrocyte differentiation. LOXL2 promotes chondrocyte differentiation by mechanisms that are likely to include roles as both a regulator and an effector of chondrocyte differentiation. LOXL2 expression could also be explored as a molecular target in the prevention of breast cancer progression.
  • $428
In Stock
Size
QTY
TargetMolTargetMolCompare
TRIM63 Protein, Rat, Recombinant (His & Myc)
TMPH-03282
E3 ubiquitin ligase. Mediates the ubiquitination and subsequent proteasomal degradation of CKM, GMEB1 and HIBADH. Regulates the proteasomal degradation of muscle proteins under amino acid starvation, where muscle protein is catabolized to provide other organs with amino acids. Inhibits de novo skeletal muscle protein synthesis under amino acid starvation. Regulates proteasomal degradation of cardiac troponin I TNNI3 and probably of other sarcomeric-associated proteins. May play a role in striated muscle atrophy and hypertrophy by regulating an anti-hypertrophic PKC-mediated signaling pathway. May regulate the organization of myofibrils through TTN in muscle cells.
  • $360
20 days
Size
QTY
TargetMolTargetMolCompare
MEK2 Protein, Human, Recombinant (GST)
TMPY-04544
Dual specificity mitogen-activated protein kinase kinase 2, also known as MAP kinase kinase 2, MAPKK2, ERK activator kinase 2, MAPK ERK kinase 2, MEK2 and MAP2K2, is a member of the protein kinase superfamily, STE Ser Thr protein kinase family and MAP kinase kinase subfamily. MAP2K2 MEK2 contains one protein kinase domain. MEK1 and MEK2 (also known as MAP2K1 and MAP2K2, respectively) are evolutionarily conserved, dual-specificity kinases that mediate Erk1 and Erk2 activation during adhesion and growth factor signaling. MAP2K1 MEK1 is a crucial modulator of Mek and Erk signaling and have potential implications for the role of MEK1 and MEK2 in tumorigenesis. MAP2K2 MEK2 catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. It also activates the ERK1 and ERK2 MAP kinases. Defects in MAP2K2 are a cause of Cardiofaciocutaneous Syndrome (CFC Syndrome) which is characterized by a distinctive facial appearance, heart defects, and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects, and hypertrophic cardiomyopathy.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
  • $398
In Stock
Size
QTY
TargetMolTargetMolCompare
CRT2 Protein, Human, Recombinant
TMPJ-01277
Calreticulin-3 belongs to the calreticulin family, members of which are calcium binding chaperones localized mainly in the endoplasmic reticulum. It can be divided into a N-terminal globular domain, a proline-rich P-domain forming an elongated arm-like structure and a C-terminal acidic domain. During spermatogenesis process, Calreticulin-3 may act as a lectin-independent chaperone for specific client proteins such as ADAM3. Defects in CALR3 are the cause of familial hypertrophic cardiomyopathy type 19 (CMH19), it is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain.
  • $116
7-10 days
Size
QTY
TargetMolTargetMolCompare
MYOZ2 Protein, Human, Recombinant (His)
TMPJ-01343
Myozenin 2 (MYOZ2) is a 264 amino acid protein that belongs to the myozenin family. MYOZ2 binds to Calcineurin, a phosphatase that is involved in calcium-dependent signal transduction in diverse cell types. MYOZ2 is one of the sarcomeric proteins and plays an important role in myofibrillogenesis and the modulation of calcineurin signaling. It may serve as intracellular binding proteins involved in linking Z line proteins such as alpha-actinin, gamma-filamin, TCAP telethonin, LDB3 ZASP and plays an important role in the modulation of calcineurin signaling. Defects in MYOZ2 are the cause of familial hypertrophic cardiomyopathy type 16 (CMH16), a hereditary heart disorder.
  • $184
7-10 days
Size
QTY
TargetMolTargetMolCompare
TRIM63 Protein, Mouse, Recombinant (His & Myc)
TMPH-02634
E3 ubiquitin ligase. Mediates the ubiquitination and subsequent proteasomal degradation of CKM, GMEB1 and HIBADH. Regulates the proteasomal degradation of muscle proteins under amino acid starvation, where muscle protein is catabolized to provide other organs with amino acids. Inhibits de novo skeletal muscle protein synthesis under amino acid starvation. Regulates proteasomal degradation of cardiac troponin I TNNI3 and probably of other sarcomeric-associated proteins. May play a role in striated muscle atrophy and hypertrophy by regulating an anti-hypertrophic PKC-mediated signaling pathway. May regulate the organization of myofibrils through TTN in muscle cells.
  • $360
20 days
Size
QTY